

Curriculum Vitae

ROGER K. CADY, M.D.

Banyan Group, Inc.
Headache Care Center; Clinvest Research
3805 S. Kansas Expressway
Springfield, MO 65807
(417) 841-3615 Fax: (417) 883-7476
rcady@banyangroupinc.com

EDUCATION

Residency:

St. Francis-Mayo Family Practice Residency, LaCrosse, Wisconsin
Chief Resident, 1980 - Graduated 1980

Medical School:

Mayo Medical School, Rochester, Minnesota
Fall, 1973. Graduated 1977. Received Mayo Alumni Award

Research:

Hormel Institute, January, 1973, through Fall, 1973.
Research in lipid biochemistry funded by National Institutes of Health research grant
to study diolphospholipids in cell membranes

College:

Drake University, Des Moines, Iowa, Fall, 1969 through Fall, 1972. Graduated
Summa Cum Laude and Phi Beta Kappa

PROFESSIONAL EMPLOYMENT

2005 - Present: CEO, Banyan Group, Inc., Springfield, Missouri
1997 - Present: Director, Clinvest, Springfield, Missouri
1996: Founder, Primary Care Network, Inc., Springfield, Missouri
1995 - Present: Director, Headache Care Center, Springfield, Missouri
1986 - 1995: Medical Director, Shealy Institute, Springfield, Missouri
1984 - 1985: Chief of Staff, St. Joseph Memorial Hospital, Hillsboro, Wisconsin
1980 - 1986: Family Practice, Hillsboro, Wisconsin

MEDICAL LICENSE

Missouri #R8F67
Wisconsin #21587

SPECIALTY CERTIFICATION

American Board of Family Practice
NBCHM Certification of Added Qualification in Headache Management
UCNS Subspecialty Certification in Headache Medicine

PROFESSIONAL SOCIETIES

American Academy of Family Physicians
American Academy of Pain Management
American Academy of Pain Medicine
American Headache Society
American Medical Association
American Society for Clinical Pharmacology and Therapeutics
Greene County Medical Society
International Headache Society
Missouri State Medical Association
National Headache Foundation
Southern Medical Association

CURRENT APPOINTMENTS

Allergan Advisory Board
Capnia, Inc. Advisory Board
Endo Pharmaceutical Advisory Board
GlaxoSmithKline Advisory Board
Johnson & Johnson Advisory Board
MedPointe, Inc. Advisory Board
Merck & Company Advisory Board
Ortho-McNeil Advisory Board
Winston Labs Advisory Board
JVIC Adjunct Faculty, Missouri State University

CURRENT BOARDS OF DIRECTORS

Banyan Group, Inc., Chairman
National Headache Foundation, Vice President
National Board for Certification in Headache Management, President

BOOKS

Brandes JL, Buse DC, Cady RK, Martin VT, Wakefield PM. *Menstrual Migraine: A Disease Overview*. Monograph based on the proceedings of the Menstrual Migraine Leadership Conference held in December 2006, , 2007 © Endo Pharmaceuticals.

Cady R, Schreiber C, Farmer, K. Analgesic Rebound Headache. In: Waldman SD, ed. *Pain Management*. Philadelphia, PA: Saunders Elsevier. Vol 1, January 2007, 492-501.

Cady RK. Headache, Cluster. In: Domino FJ, ed. *5-Minute Clinical Consult 2007*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:520-521.

Cady RK. Migraine. In: Damino FJ, ed. *5-Minute Clinical Consult 2007*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:778-781.

Cady RK. Headache, Cluster. In: Dambro MR, ed. *2006 Griffith's 5-Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:464-465.

Cady RK. Migraine. In: Dambro MR, ed. *2006 Griffith's 5-Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:706-707.

Cady RK. Lessons from patient care: case studies of migraine patients. In: Jeffrey Unger, ed. *Clinics in Family Practice: Migraine*. Philadelphia, PA: W.B. Saunders. Vol. 7, No 2. September 2005, 579-601.

Cady RK. The case of one headache disguised as another. In: Purdy RA, Rapoport AM, Sheftell FD, Tepper SJ, eds. *Advanced Therapy of Headache*. Hamilton, Ontario:BC Decker Inc; 2005:243-248.

Cady RK. Headache, Cluster. In: Dambro MR, ed. *2005 Griffith's 5-Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:462-463.

Cady RK. Migraine. In: Dambro MR, ed. *2005 Griffith's 5 Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:704-705.

Cady RK, Schreiber CP. Sinus headache: a clinical conundrum. In: Spiegel JH, guest ed. *Otolaryngologic Clinics of North America; Sinusitis*. Vol 37. No 2. April 2004, 267-288.

Cady RK, Schreiber CS, Farmer K. Tension-type headache. In: Loder EW, Martin VT, eds. *Headache: A Guide for the Primary Care Physician*. Philadelphia, Pa: American College of Physicians; 2004,79-93.

Farmer K, Cady R. Other approaches to migraine management. In: Loder E, Marcus DA, eds. *Migraine in Women*. Hamilton, Ontario: BC Decker Inc; 2004:85-94.

Cady RK. Headache, Cluster. In: Dambro MR, ed. *2004 Griffith's 5 Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:460-461.

Cady RK. Migraine. In: Dambro MR, ed. *2004 Griffith's 5 Minute Clinical Consult*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:700-701.

Cady RK, Farmer K, Schreiber CP, Kaniecki R. The usefulness of the publication, patient-centered strategies for effective management of migraine in primary care. In: Olesen J, Steiner TJ, Lipton RB, Eds. *Reducing the Burden of Headache*. Vol. II, New York, NY: Oxford University Press; 2003:402-407.

Bayliss MS, Bjorner JB, Kosinski M, Dahlöf CGH, Dowson A, Cady RK, Ware JE Jr, Batenhorst AS. Development of HIT-6™, a paper-based short form for measuring headache impact. In: Olesen J, Steiner TJ, Lipton RB, Eds. *Reducing the Burden of Headache*. Vol. II, New York, NY: Oxford University Press; 2003:386-390.

Schreiber CP, Cady RK. Self-described 'sinus headache' and headache related impact. In: Olesen J, Steiner TJ, Lipton RB, eds. *Reducing the Burden of Headache: Frontiers in Headache Research Series*. Vol. 11. New York, NY: Oxford University Press; 2003:189-193.

Farmer K, Cady RK, Reeves D, Bleiberg J. Cognitive efficiency following migraine therapy. In: Olesen J, Steiner TJ, Lipton RB, eds. *Reducing the Burden of Headache: Frontiers in Headache Research Series*. Vol. 11. New York, NY: Oxford University Press; 2003:46-51.

Cady RK, Farmer KU, Schreiber CP, et al. *Patient-Centered Strategies for Effective Management of Migraine*. Springfield, Mo: Primary Care Network; 2000.

Cady RK. *Advances in migraine treatment: the era of the triptans*. Richmond, Virginia Commonwealth University. 1999

Cady RK. Cluster headache. In: Dambro MR, ed. *1998 Griffith's 5 Minute Clinical Consult*. Baltimore, Md: Williams & Wilkins; 1998:448-449.

Cady RK. Migraine. In: Dambro MR, ed. *1998 Griffith's 5 Minute Clinical Consult*. Baltimore, Md: Williams & Wilkins; 1998:678-679.

Cady RK, Farmer K. Post traumatic headache. In: Windsor R, Lox D, eds. *Soft Tissue Injuries*. Philadelphia, Pa: Hanley and Belfus; 1998:207-224.

Cady RK, Solomon GD, Klapper J, Ryan R. *Practice Standard Guidelines for Treatment of Headache*. Chicago, Ill: National Headache Foundation; 1997.

Cady RK. *Migraine and Other Headaches*. Chicago, Ill: American Medical Association; 1996.

Cady RK, Farmer K. *Headache Free*. New York, NY: Bantam Books; 1996.

Cady RK, Klapper J, Ryan R, Mishkin B. *Standards of Care for Headache Diagnosis and Treatment*. Chicago, Ill: National Headache Foundation; 1996.

Cady RK, Fox AW, eds. *Treating the Headache Patient*. New York, NY: Marcel Dekker; 1995.

Cady RK, Solomon GD, Tepper S, Rosum RW. *Rational Therapy: Headache*. Waltham, Mass: Institute for Contemporary Pharmacy Research; 1995.

Shealy CN, Cady RK. Multidisciplinary pain clinics. In: Wiener RS, ed. *Innovations in Pain Management*. Orlando, Fla: Paul M. Deutsch Press, Inc.; 1990;1:4-1 to 4-20.

Shealy CN, Cady RK. The history of pain management. In: Wiener RS, ed. *Innovations in Pain Management*. Orlando, Fla: Paul M. Deutsch Press, Inc.; 1990;1:2-1 to 2-21.

ARTICLES

Cady RK, Schreiber CP. Botulinum toxin type A as migraine preventive treatment in previously noncompliant patients. *Headache*. Nov 2007; Published OnlineEarly

Hu XH, MD, Ng-Mak D, Cady R. Does Early Migraine Treatment Shorten Time to Headache Peak and Reduce Its Severity? *Headache*. Nov 2007; Published OnlineEarly.

Martin V, Cady R, Mauskop A, Seidman LS, Rodgers A, Hustad CM, Ramsey KE, RPh; Skobieranda F. Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies. *Headache* Nov 2007; Published OnlineEarly.

Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, et al. The impact of Topiramate on health-related quality of life indicators in chronic migraine. *Headache*. 2007; Pending.

Cady RK, Farmer KU, Beach M.E., Tarrasch J. Nurse-based education: an office-based comparative model for education of migraine patients. *Headache*. 2007; Pending

R Cady, V Martin, A Mauskop, A Rodgers, Cm Hustad, Ke Ramsey, F Skobieranda. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. *Cephalalgia*. 2007;27:1055-1060.

Silberstein SD, Cady RD, MD, Sheftell FD, et al. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. *Headache*. 2007;47: 673–682.

Ng-Mak DS, Cady R, Chen YT, et al. Can migraineurs accurately identify their headaches as "migraine" at attack onset? *Headache*. 2007;47:645–653.

Roger Cady, MD. Pathophysiology of Migraine. *The Pain Practitioner*. Spring 2007; 17(1): 6-15.

Mathew NT, Finlayson G, Smith T, Cady, RK, et al. Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT[®] Early Migraine Intervention Study). *Headache*. 2007;47:189-198.

Roger K Cady, Kathleen Farmer-Cady. Evidence-based behavioral management of migraine. *Migraine Consult Collection*. February 2007:2-6.

Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan–naproxen sodium for the treatment of acute migraine. *Mayo Clin Proc*. 2007; 82(1):61-68.

Newman L, Silberstein S, Cady R, et al. Understanding the pathophysiology of menstrual migraine. *National Menstrual Migraine Coalition Courier*. December 2006;1(2).

Farmer K, Cady R. Case Study: Transformation from episodic migraine to chronic neurological disease. *The Pain Practitioner*. Fall 2006;16(3): 34-40.

Cady R, Schreiber C. Sumatriptan: Update and review. *Expert Opinion on Pharmacotherapy*. August 2006, 7(11):1503-1514.

Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. *Headache*. 2006;46:914-924.

Cady RK. Pathophysiology of migraine: Implications to patient care. *Tex Dent J*. 2006 Feb;123(2):142-151.

Cady RK, Biondi DM. An update on migraine pathophysiology and mechanism-based pharmacotherapeutics for migraine. *A Special Report from Postgraduate Medicine*. April 2006: 5-13.

Cady RK. Supplements for the Prevention of Headache. *NHF Headlines*. March/April 2006; No 149:1-3.

Levine HL, Setzen M, Cady RK, Dodick DW, Schreiber CP, Eross EF, et al. An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headache. *Otolaryngology Head Neck Surg*. March 2006;134(3):516-523.

Revicki DA, Kimel M, Beusterien K, Kwong JW, Varner JA, Ames MH, Mahajan S, and Cady RK. Validation of the revised patient perception of migraine questionnaire; measuring satisfaction with acute migraine treatment. *Headache*. Feb. 2006;46:240-252.

Cady R, Schreiber C. Frovatriptan: clinical review and future directions. *Future Neurology*. January 2006;1(1):13-19.

Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, and Kuhn TA. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. *Headache*. 2006;46(1):115-124.

Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. *Headache*. 2006;46(1):24-33.

Cady R. Migraine prevention. *Primary Care Special Edition*. McMahon Publishing Co; December 2005 (Special Report).

Cady RK. Menstrual migraine: pathophysiology and diagnosis. A supplement to *The Female Patient*®; OB/GYN edition. December 2005:8-10.

Cady RK. Acute Treatment of Menstrually Related Migraine. *Advanced Studies in Medicine*. 2005 Oct;5(9A):S783-S789.

Cady RK, Schreiber CP, Beach ME, Hart CC. Gelstat Migraine® (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. *Med Sci Monit*. 2005 Sep;11(9):PI65-P169.

Brandes JL, Kudrow K, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. *Cephalalgia*. 2005;25(9):735-742.

Sheftell FD, Cady RK, Borchert LD, Spalding W, Hart CC. Optimizing the diagnosis and treatment of migraine. *J Am Acad Nurse Pract*. 2005;17(8):309-317.

Cady RK, Dodick DW, Levine HL, Schreiber CP, Eross EJ, Setzen M, et al. Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. *Mayo Clinic Proceedings*. 2005 July; 80(7):908-916.

Foley KA, Cady RK, Martin V, Adelman J, Diamond M, Bell CF, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. *Headache*. 2005; 45:538-545.

Diamond M, Cady RK. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. *Am J Med*. 2005;118(suppl 1):S18-S27.

Cady R, Farmer K, Dexter JK, Schreiber C. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. *Cur Pain Head Rep*. 2005 Feb;9(1):47-52.

Wenzel RG, Lipton RB, Diamond ML, Cady RK. Migraine therapy: a survey of pharmacists' knowledge, attitudes, and practice patterns. *Headache*. 2005;45(1):47-52

Cady R. The convergence hypothesis: implications for diagnosing and managing migraine. *CNS News*. 2004 Sept;6(9):43-48.

Cady RK, Schreiber CP. Patient-centered strategies for migraine: optimizing migraine care. *Migraines and Managed Care Newsletter*. 2004;1(1):1-8.

Cady RK. Life between headache attacks: looking at the patient not the migraine. *ACHE Newsletter: Headache*. Winter 2004;15(4):5-7.

Cady RK, MD. "Ask the doctor". *ACHE Newsletter: Headache*. Summer 2004;15(2):10.

Cady R. Better, faster therapies for migraine headache. *The Clinical Advisor*. 2004 July;21-30.

Cady R. The new thinking about migraine headache. *Cortlandt Forum*. 2004 June; 17(6):33-41.

Cady R, Martin V, Adelman J, Diamond M, Sajjan S, Hu XH. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study. *Headache*. 2004 Oct;44(9):900-907.

Cady RK, Adelman J, Taylor F, et al. Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid-release tablets: results of a randomised, placebo-controlled study conducted in the USA and Canada. *Headache Care*. 2004;1(4):281-284.

Cady, RK. Choosing an effective strategy of migraine care. *NHF HeadLines*. 2004 Sep/Oct;No.140:1-3.

Cady RK, Borchert LD, Spalding W, Hart CC, Sheftell FD. Simple and efficient recognition of migraine with a 3-question headache screen. *Headache*. 2004;44:323-327.

Cady RK, Elkind A, Goldstein J, et al. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. *Current Medical Research and Opinion*. 2004;20(9):1465-1472.

Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: the evolution from episodic headache to chronic neurological disease. *Headache*. 2004 May;44:426-435.

Cady RK, Schreiber CP, Farmer KU. Understanding migraine: advancing from clinical trials to clinical practice. *Headache Care*. 2004;1(3):183-190.

Dahlöf C, Cady R, Poole AC, et al. Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid-release tablets: pooled results of two replicate, randomised, placebo-controlled studies. *Headache Care*. 2004;1(4):277-280.

Dowson AJ, Cady RK, Tepper SJ, Smith TR, Shaper G. Pharmacologic management of migraine. *Annals of Internal Medicine*. 2004 Mar;140:W-26.

Dowson AJ, Tepper SJ, Cady RK. New initiatives for the management of headache in primary care: review of the headache care for practicing clinicians (HPCP). *Headache Care*. 2004;1(1):7-13.

Durham PL, Cady R, Cady RK. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin Type A: implications for migraine therapy. *Headache*. 2004;44:35-43.

Freitag FG, Lake A, Lipton R, Cady R. On behalf of the US Headache Guidelines Consortium, Section on Inpatient Treatment, Chairpersons: Seymour Diamond, MD; Stephen Silberstein, MD. Inpatient treatment of headache: an evidence-based assessment. *Headache*. 2004;44:342-360.

Taylor F, Hutchinson S, Graff-Radford S, Cady R, Harris L. Diagnosis and management of migraine. *The Journal of Family Practice*, (Suppl) 2004 Jan; S1-S24.

Visser WH, Winner P, Strohmaier K, Cady R, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. *Headache*. 2004;44:891-899.

Wenzel R, Dortch M, Cady R, Lofland JH, Diamond S. Migraine headache misconceptions: barriers to effective care. *Pharmacotherapy* 2004;24(5):638-648.

Cady R. Migraine in our midst: better ways to seek and find. *CNS News: Neurology Edition*. McMahon Publishing Company, 2003 July;5(7).

Cady R, Farmer K, Schreiber C. Skeletal muscle relaxants: a new rationale for choice. *Primary Care Special Edition*. McMahon Publishing Company; 2003 July (Special Report).

Cady RK, Borchert LD, Spalding W, Hart CC, Sheftell FD. Diagnosing migraine with a simple and efficient 3-question headache screen. Poster presented at: 128th Annual Meeting of the American Neurological Association; October 20, 2003; San Francisco, CA.

Dowson AJ, Sender J, Lipscombe S, Cady RK, Tepper SJ, Smith R, Smith TR, Taylor FR, Boudreau GP, Van Duijn NP, Poole AC, Baos V, Woeber C. Establishing principles for migraine management in primary care. *International Journal & Clinical Practice*. 2003;57:493-507.

Bayliss MS, Dewey JE, Dunlap I, Batenhorst AS, Cady RK, Diamond ML, et al. A study of the feasibility of Internet administration of a computerized health survey: the headache impact test (HIT). *Quality of Life Research*. Dec 2003;12(8):953-961.

Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. *Quality of Life Research*. 2003 Dec;12(8):963-974.

Kosinski M, Bjorner JB, Ware JE Jr, Batenhorst A, Cady RK. The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: a re-analysis of three clinical trials. *Quality of Life Research*. 2003 Dec;12(8):903-912.

Unger J, Cady RK, Farmer-Cady K. Part Three; Understanding migraine: strategies for prevention. *Emergency Medicine*. 2003 Oct;35(10):39-45.

Unger J, Cady RK, Farmer-Cady K. Part Two; Understanding migraine: treatment options. *Emergency Medicine*. 2003 Sep;35(9):50-55.

Unger J, Cady RK, Farmer-Cady K. Part One; Understanding migraine: pathophysiology and presentation. *Emergency Medicine*. 2003 Aug;35(8):22-32.

Unger J, Cady RK, Farmer-Cady K. Migraine headaches, Part 3: hormonal factors. *The Female Patient* . 2003 Jul;28(7):31-34.

Unger J, Cady RK, Farmer-Cady K. Migraine headaches, Part 2: treatment options. *The Female Patient* . 2003 Jun;28(6):22-29.

Unger J, Cady RK, Farmer-Cady K. Migraine headaches, Part 1: presentation and diagnosis. *The Female Patient* . 2003 May;28(5):32-39.

Weidmann E, Unger J, Blair S, Friesen C, Hart C, Cady R. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. *Clinical Therapeutics* 2003 Jan;25(1)235-246.

Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: A pooled analysis. *Headache*. 2002 Jan;42(suppl 1):S26-S31.

Cady R, Dodick D, Kaniecki RG, Lipton RB, Schreiber C. The expanding spectrum of migraine. Primary Care Network. McMahon Publishing Company. 2002 (special report).

Cady R, Dodick DW. Diagnosis and treatment of migraine. *Mayo Clinic Proceedings*. 2002;77:255-261.

Cady R, Schreiber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. *Headache*. 2002;42:204-216.

Cady RK. Distinguishing "sinus headache" from migraine headache. *Johns Hopkins Advanced Studies in Medicine*. 2002 Sep;2(16).

Cady RK. Strategies for engaging Primary Care. *Product Management Today*[®]. 2002 Jul;13(7):45-47.

Cady RK. Headache: why the "default diagnosis" needs to be migraine. *Consultant*. 2002;42(Suppl)No.13, S4-S5.

Cady RK, Loder E. Medical Crossfire. Improving migraine management: the challenge before primary-care physicians. 2002 Jul;4(7):37-47.

Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. *Neurology*. 2002 May;58(Suppl 6):S10-S14.

Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. *Headache*. 2002 Nov/Dec; 42(10):984-999.

Lipton RB, Cady R. Mixing sumatriptan. *Headache*. 2002 Apr;42(4):325-326.

Lipton RB, Cady RK, Stewart WF, Wilks K, Hall C. Diagnostic lessons from the spectrum study. *Neurology*. 2002 May;58(Suppl 6):S27-S31.

Ryan R, Géraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. *Headache*. 2002;42(Suppl 2):S84-S92.

Allen C, Cady R, Lines C, McCarroll K. Effect of rizatriptan in the spectrum of headache. *Headache*. 2001 Jun;41(6):607-608.

Cady R. Looking forward: the expanding utility of sumatriptan and naratriptan. *Cephalalgia*. 2001;21(Suppl 1):35-38.

Cady R, Crawford G, Ahrens S, Hairwassers D, Getson A, Visser WH, Lines C, on behalf of the Rizatriptan-RPD Study Group. Long-term efficacy and tolerability of rizatriptan wafers in migraine. *MedGenMed*. 2001 Jun 01;3(3):1.

Cady R, Keywood C. Frovatriptan: preliminary efficacy in the early treatment of migraine attacks. *Cephalalgia*. 2001;21:426-427. Poster presented at: International Headache Congress; 2001 Jun; New York, NY.

Cady RK. Early intervention in the treatment of migraine. *Headache Quarterly*. 2001; 12(suppl 1):3-8.

Cady RK. Treatment strategies for migraine headache. *JAMA*. 2001 Feb 28;285 (8):1014-1015.

Cady RK, Sheftell F, Lipton RB, Kwong WJ, O'Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. *Clinical Therapeutics*. 2001; 23:284-291.

Farmer KU, Cady RK, Bleiberg J, Reeves D. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. *Headache*. 2001;41:377-384.

Freitag FG, Cady RK, DiSerio F, Elkind A, Gallagher RM, Goldstein J, Klapper JA, Rapoport AM, Sadowsky C, Saper JR, Smith TR. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. *Headache*. 2001;41:391-398.

Lofland JH, Kim SS, Batenhorst AS, Johnson NE, Chatterton ML, Cady RK, Kaniecki R, Nash DB. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. *Mayo Clinic Proceedings*. 2001;76:1093-1101.

Sheftell F, Dodick D, Cady R. Direct-to-consumer advertising of OTC agents under current ftc regulations: concerns and comment. *Headache*. 2001 Jun;41(6):534-536.

Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity. A review of the impact of migraine and its treatment. *Pharmacoeconomics*. 2001;19(3):231-244.

Cady RK, Farmer-Cady K. Migraine: changing perspectives on pathophysiology and treatment. *Consultant*. 2000;40:S13-S19.

Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled headache sufferers: results of the spectrum study. *Headache*. 2000;40:792-797.

Cady RK, Powers C, Szeto S, et al. Evaluation of migraineurs preferences for naratriptan over conventional first-line agents. *Archives of Family Medicine*. 2000;9:753-757.

Cady RK, Sheftell F, Lipton, RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. *Clinical Therapeutics*. 2000;22:1035-1048.

Farmer KU, Cady RK, Bleiberg J, Reeves D. A pilot study to measure cognitive efficiency during migraine. *Headache*. 2000;40:657-661.

Lipton RB, Stewart WF, Cady RK, Hall C, O'Quinn S, Kuhn T, Gutterman D. Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study. Recipient of 2000 Wolff Award. *Headache*. 2000;40:783-791.

Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady RK. Prevention of migraine during prodrome with naratriptan. *Cephalalgia*. 2000;20:122-126.

Schulman FA, Cady RK, Henry D, Batenhorst AS, Putnam DG, Watson CB, O'Quinn SO. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. *Mayo Clinic Proceedings*. 2000;75:782-789.

Cady, RK. Diagnosis and treatment of migraine. *Clinical Cornerstone*. 1999;1:21-32.

Cady, RK. Focus on primary care female population with migraine. *Obstetrical and Gynecological Survey*. 1999; 54(12 Suppl Focus):S1-S7.

Cady, RK. Primary care in a health maintenance organization. *Cephalalgia*. 1999;19:541-542.

Cady, RK. Reduction of labor costs associated with treating migraine in the workplace. *Archives of Internal Medicine*. 1999;159(2):197.

Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack. results of a double-blind, placebo-controlled trial. *Archives of Internal Medicine*. 1998 May 11;158(9):1013-1018.

Cady, RK. Computerized migraine care. *Cephalalgia*. 1998;18:419-420.

Cady RK, Farmer KU. What patients need to know about managing migraine. *Postgraduate Medicine*. 1998;31-36.

International Study Group. (Cady, RK corresponding author). The long-term tolerability and efficacy of oral zolmitriptan in the acute treatment of migraine. *Headache*. 1998;38:173-183.

Cady RK, Farmer KU. Principles of chronic pain management for the primary care physician. *Journal of Clinical Outcomes Management*. 1997;4:37-43.

Cady RK, Gutterman D, Saiers JA, Beach ME. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. *Cephalalgia*. 1997;17:588-590.

Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of the 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. *Neurology*. 1997;49:1219-1225.

Solomon GD, Cady RK, Klapper J, Lowy MT, on behalf of the US 311C90 2.5 mg Study Group. Confirmation of the efficacy and safety of a 2.5 mg dose of 311C90 in the acute treatment of migraine. Presented at: 121st Annual Meeting of the American Neurological Association; April, 1997; Boston, Mass.

Solomon GD, Cady RK, Klapper JA, Ryan RE Jr. Standards of care for treating headache in primary care practices. *Cleveland Clinic Journal of Medicine*. 1997 Jul/Aug;64(7):373-383.

Cady RK. Prophylactic therapy of migraine in primary care. *Headache Quarterly*. 1996;7:6-12.

Cady RK, Farmer K, Griesemer K, Sable J. Prevalence of headache in children. *Headache Quarterly*. 1996;7:312-318.

Cox RH, Shealy CN, Cady RK, et al. Significant magnesium deficiency in depression. *Journal of Neurological and Orthopaedic Medicine & Surgery*. 1996;17:7-9.

Halverson LW, Cady RK, Diamond ML, Solomon GD. Severe headache outcomes and the patient. *Hospital Physician*. 1996 Apr;20-36.

Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. *Journal of Family Practice*. 1996;42:36-42.

Klapper JA, Cady RK, et al. Experience with divalproex sodium as a new agent in migraine prophylaxis. *Headache Quarterly*. 1996;7:20-23.

Lowry MT, Cady RK, on behalf of the US 311C90 2.5 mg Study Group. 2.5 mg 311C90 in the acute treatment of migraine: efficacy and safety. Presented at: 2nd Congress of the European Federation of Neurological Societies (Abstract); November 1, 1996; Rome, Italy.

Mushet GR, Cady RK, Baker CC, Clements B, Gutterman DL, Davis R. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. *Clinical Therapeutics*. 1996 Jul/Aug;18(4):687-699.

Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R, Saiers J, Fox AW. Analgesic rebound headache in clinical practice; data from a physician survey. *Headache*. 1996 Jan;36(1):14-19.

Shealy CN, Cady RK, Cox RH, Murrell.M. DHEA deficiency in patients with chronic pain and depression. *Journal of Neurological and Orthopaedic Medicine and Surgery*. 1996;17:6.

Cady RK. Migraine and related headache disorders. *Orthopaedic Physical Therapy Clinics of North America*. 1995;4:485-502.

Halverson LW, Cady RK. Dilemmas of decision making in a case of severe headache. *Journal of Clinical Outcomes Management*. 1995;2.

Rapoport AM, Cady RK, Matthew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL, Brown L. Optimizing the oral dose of 311C90 in the acute treatment of migraine. *Cephalalgia*. 1995;15 (suppl 14):221.

Shealy CN, Cady RK, Cox RH. Pain, stress and depression: psychoneurophysiology and therapy. *Stress Medicine*. 1995;11:75-77.

Cady RK, Rubino J, Crummett D, Littlejohn III T. Oral sumatriptan In the treatment of recurrent headache. *Archives of Family Medicine*. 1994 Sep;3(9):766-772.

Cady RK. Advances in migraine management: focus on sumatriptan. *Resident and Staff Physician*. 1993;39:49-56.

Cady RK, Shealy CN. Recent advances in migraine management. *The Journal of Family Practice*. 1993;36(No 1):85-91.

Cady RK, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. *Neurology*. 1993 Jul;43(7):1363-1368.

Shealy CN, Cady RK, et.al. The neurochemistry of depression. *American Journal of Pain Management*. 1992;2(No 1).

Cady RK. et al. Treatment of acute migraine with subcutaneous sumatriptan. *Journal of the American Medical Association*. 1991;265:2831-2835.

Shealy CN, Cady RK. Neurochemical response to central electrical stimulation and brain synchronization. (Abstract) VI International Rehabilitation Medicine Association; XIV National Congress of the Spanish Rehabilitation Society. *Excerpta Medica, International Congress Series 927*, 1990 Jun, S.27.1.

Shealy CN, Cady RK, Wilkie RG, Cox RH, Liss S, Clossen W. Depression: a diagnostic, neurochemical profile and therapy with cranial electrical stimulation (CES). *The Journal of Neurological and Orthopaedic Medicine and Surgery*. 1989 Dec;10(4):319-21.

Shealy CN, Cady RK, Wilkie RG, Cox RH, Liss S, Clossen W. Depression: a diagnostic, neurochemical profile and therapy with cranial electrical stimulation (CES). *Energy Fields in Medicine*. The John E. Fetzer Foundation, Kalamazoo, Mich: 1989; 446-457.

Shealy CN, Cady RK, Wilkie RG, Cox RH. Facet rhizotomy/denervation: a fifteen year experience. *The Journal of Neurological & Orthopaedic Medicine & Surgery*. 1988;9:107-108.

Shealy CN, Cady RK, Wilkie RG, Cox RH. Neurochemical changes in patients with chronic pain and depression. (Abstract) 82nd Annual Scientific Assembly of the Southern Medical Association, 1988;37.

Shealy CN, Cady RK, Wilkie RG, Cox RH. Spinal and referred pain: nemesis of the harried physician. *The Journal of Neurological and Orthopaedic Medicine and Surgery*. 1988;9:305-306.

Cady RK. Electrotherapy in medicine. *California Dental Association Journal*. 1987 Jun.

Cady RK, Shealy CN. Electronic anesthesia. *CDA Journal*. 1987 Jun;15(6):22-25.

PRESENTATIONS

Dr. Cady has presented countless lectures and seminars at local, state, national, and international meetings on headache and pain disorders.

CLINICAL RESEARCH - Principal Investigator

Abbott Laboratories

- | | |
|---------|--|
| M03-648 | Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study |
| M02-488 | The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Double-Blind, Placebo-Controlled Study in Adolescents |
| M98-845 | The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Double-Blind, Placebo-Controlled Study |

Advanced Bionics

- | | |
|-------|--|
| Prism | Precision implantable Stimulator for Migraine Occipital Nerve Stimulation (ONS) for Migraine |
|-------|--|

Alexza

- AMDC-104-201 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients with Migraine Headache
- AMDC-001-202 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety Outpatient Study of Staccato™ Prochlorperazine for Inhalation Patients with Migraine Headache
- AMDC-001-201 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Staccato Prochlorperazine for Inhalation in Patients with Migraine Headache

Alizyme Therapeutics, Ltd.

- ATL1251/038/CL A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
- ATL1251/052/CL A Phase III, Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

Allergan

- 191622-080-00 A Multi-Center Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase
- 191622-079-00 A Multi-Center Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase
- 191622-005 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of Two Doses of BOTOX® (Botulinum Toxin, Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Chronic Migraine Headaches
- 191622-027-00 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into Bilateral Pericranial Muscles for the Prophylactic Treatment of Chronic Tension Type Headache

Astra Zenecca

- 311CUS/0015 A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan 5 mg Orally Disintegrating Tablet When Taken as Soon as Possible After the Onset in the Acute Treatment of Migraine Headache
- 311CUS/0014 A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan (Zomig) 2.5 mg Orally Disintegrating Tablet When Taken as Soon as Possible After the Onset in the Acute Treatment of Migraine Headache
- 311CUS/0016 A Multi-Center, Randomized, Open-Label Comparison of the Effects of Zomig-ZMT (zolmitriptan) and Usual Migraine Care on Work Loss, Productivity and Patient Preference
- 311CUS/0022 A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine

Bayer

- 100306 A Single-Arm, Open Label Study of Cerivastatin in Community-Based Patients with Hypercholesterolemia at Risk for Cardiovascular Disease and Patients with Cardiovascular Disease
- S98-074 A Multi-Center, Prospective, Randomized, Double-Blind, Parallel Group, Single Dose, Placebo-Controlled Study of the Efficacy of Extra Strength Bayer Aspirin (1000 mg) in Subjects with Acute Migraine Attacks
- 100398 Prospective, Randomized, Double-Blind, Multi-Center, Comparative Trial to Evaluate the Efficacy and Safety of Ciprifloxacin Once Daily Extended Release 500 mg Tablets QD for 3 days

BioAlliance

- BA/2005/21/02 A Randomised, Double-Blind, Single-dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients" LIP Study (Lauriad Immunocompetent Patients Study)

Bristol-Myers Squibb

- 134-01-99 Efficacy and Safety of the Combination Product Acetaminophen, Aspirin, and Caffeine Compared to Ibuprofen and to Placebo in the Acute Treatment of Migraine Attacks

133-01-99 Efficacy and Safety of the Combination Product Acetaminophen, Aspirin, and Caffeine Compared to Ibuprofen and to Placebo in the Acute Treatment of Episodic Tension-Type Headaches

Burroughs Wellcome

136-017 A Study to Confirm the Efficacy and Safety of 311C90 in the Treatment of Acute Migraine Headache

136-15 Open Study to Investigate the Long Term Effects of Oral 311C90 in the Treatment of Migraine Headache

136-042 Study to Confirm the Efficacy and Safety of a 2.5 mg. Dose of 311C90 in the Acute Treatment of Migraine Headache

Capnia

CH-2004-03 Phase II Multi-Center, Randomized, Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of CAP3 in the Treatment of Acute Migraine (ESCAPE)

Ciba-Geigy

035 A Comparative Trial of Diclofenac Potassium, Ibuprofen, and Placebo in Patients with Pain Secondary to Tension-Type Headache

Cipher

TRAMCT.02.05 A Double-Blind, Randomized, Placebo-Controlled, Multi-Dose, Phase III, Parallel-Group Study of Tramadol ER for the Management of Moderate to Moderately Severe Chronic Pain of Osteoarthritis of the Hip and Knee in Adults

Eisai Inc.

E2020-A100-213 Extension of E2020-A001-211

E2020-A001-211 A 20-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Preliminary Study to Evaluate the Efficacy and Safety of Two Fixed Doses (5 mg and 10 mg) of Donepezil Hydrochloride (E2020) in Migraine Prophylaxis

Elan Pharmaceuticals

AN46046-228 A Double-Blind, Randomized, Multi-Center, Parallel Dose Study to Evaluate the Safety and Efficacy of Zonisamide 150 mg and 300 mg Per Day and Placebo in Subjects with Migraine Headache

GelStat Corporation

An Open Label, Single-Dose Pilot Study to Evaluate the Potential Efficacy of GelStat Migraine as an Acute Treatment for Relief of Migraine

An Open-Label Study to Evaluate the Efficacy and Cost Effectiveness of GelStat Migraine as a First Line, Early Intervention, Acute Treatment for Relief of Migraine in Triptan Users

GlaxoSmithKline

- ADC109043 Incidence of airway obstruction consistent with chronic Obstructive pulmonary disease (COPD) in subjects with a history of cigarette smoking and symptoms of chronic bronchitis in a primary care setting
- TXA107563 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of TREXIMA™ (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed with Probable Migraine Without Aura (ICHD-II 1.6.1)
- COR103561 A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG-MR) with Metoprolol Succinate (Toprol-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients
- TRX105850 A Randomized, Double-Blind, Single Migraine Attack, Placebo-Controlled, Parallel-Group Multi-Center Study to Evaluate the Efficacy and Tolerability of Trexima™ (Sumatriptan Succinate/ Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women with Dysmenorrhea
- TRX103632 A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for Trexima™ (Sumatriptan 85 mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks
- SB-767905/014 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5 mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
- SUM2033 A Randomized, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study to Investigate the Efficacy and Tolerability of 100 mg Sumatriptan Administered as a Film-Coated, Fast Disintegrating Tablet
- SUM30045 A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Two Dose Levels (5 mg and 20 mg) of Sumatriptan Nasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs (12-17 Years of Age)

SUM30047	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50 mg and 100 mg in the Acute Treatment of Migraine
SUM40275	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Evaluation of Sumatriptan 50 mg and 100 mg vs Placebo During a Migraine Headache at the First Sign of Pain
SUM40285	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Evaluation of Sumatriptan 50 mg and 100 mg Tablets Administered During the Mild Phase of a Menstrually-Associated Migraine Attack
SUM40286	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study of Sumatriptan 6 mg Injection in the Treatment of Moderate-to-Severe Migraine Present Upon Awakening
SUM40299	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of Oral Sumatriptan 25 mg, 50 mg and 100 mg Tablets for a Single Moderate or Severe Headache in Adults Diagnosed with Migrainous Disorder (IHS 1.7)
IMT-R88	Development and Psychometric Assessment of a Patient Satisfaction Questionnaire with Migraine Therapy
SLGA5011	A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subject Receiving Either Usual Pharmacotherapy or Usual Pharmacotherapy Plus Salmeterol 42 mcg Twice Daily
S2B-301	Evaluation of the Safety and Efficacy of Subcutaneous GR43175C in Patients with Acute Migraine Attacks
S2B-305	Multi-Center Evaluation of the Safety and Efficacy of Subcutaneous GR43175C in Patients with Acute Migraine Attacks Using a Two-Dose Regimen
S2B-216	Safety and Efficacy of Three Doses of GR43175C in Acute Migraine Treatment
S2B-307	Repeat-Dose Efficacy and Lab Safety Trial of Subcutaneous GR43175C in Migraine Patients
S2B-308	Evaluation of Sumatriptan in the Treatment of Migraine Pain Recurrence - a Pilot Study
S2B-308E	Extension of S2B-308
S2B-211	Subcutaneous Sumatriptan as Treatment of Migraine Headache in Patients Admitted to the Emergency Department
HOL-001	A Pilot Survey of the Cardiovascular Correlations of Migraine

S2B-352	A Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks
S2B-402	The Impact of Oral Sumatriptan on the Productivity, Quality of Life, and Health Care Use in Nursing Personnel with Migraine
S2B-350	Imitrex Post-Marketing Surveillance Study
S2WA3003	A Study to Evaluate the Efficacy of Oral Naratriptan in the Acute Treatment of Four Migraine Attacks
SUMA4004	A Study to Evaluate the Impact of Imitrex Injection on Work Place Productivity Loss Due to Migraine
S2WA3012	A Study to Evaluate the Efficacy, Safety and Tolerability of Oral Naratriptan in an Adolescent Migraine Population
SUMA3005	A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Three-Dose Levels of Sumatriptan Nasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs
SUMA3006	An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sumatriptan Nasal Spray in the Acute Treatment of Multiple Migraine Attacks in Adolescent Migraineurs
SUMA4014	A Study to Evaluate the Efficacy of a Second Sumatriptan Succinate Tablet in the Acute Treatment of Migraine
SUMA4013	A Randomized, Double-Blind, Double-Dummy, Crossover, Pilot Study to Compare the Efficacy and Safety of Sumatriptan 25 mg Tablets vs Midrin Capsules in the Acute Treatment of Migraine
SUM40294	Identification of Migraine Headache Among Self-Described and/or Physician-Diagnosed Sinus Headache Sufferers and Treatment with Imitrex [®] 50 mg Tablets
SUM40298	A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group, Evaluation of the Efficacy of Sumatriptan 50 mg Tablets vs Placebo in the Treatment of Self-Described and/or Physician-Diagnosed Sinus Headaches that Meet International Headache Society Criteria for Migraine Headache
IMR-01	A Randomized, Double-Blind, Placebo-Controlled Study of Oral Sumatriptan in the Acute Treatment of Disabling Primary Headaches (Migraine, Migrainous Headache, and Episodic Tension-Type Headache)
IMT-R	Evaluation of Sumatriptan Plus Celecoxib for the Acute Treatment of Migraine and for Prevention of Recurrence Following Acute Treatment of Migraine

S2WA4006	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Oral Naratriptan 1 mg and 2.5 mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine
GL230018	A Study in the Prophylaxis of Migraine Headache Attacks in Adult Subjects with Migraine
S2W40012	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Oral Naratriptan 1 mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine
S2W40027	An Open-Label Evaluation of the Long-Term Safety of Oral Naratriptan 1 mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine
GL230016	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Tolerability and Efficacy of 12-Week Oral GV196771 300 mg Once Daily Compared to Placebo in the Prophylaxis of Migraine Headache
GH040031	A Randomized, Parallel-Group Evaluation of the Effect of Implementing the Headache Impact Test (HIT) in General Practice on the Quality of Headache Care
101429	An Evaluation of Satisfaction and Efficacy of the Newly Formulated 100 mg Sumatriptan Tablet in a Very Early Intervention Paradigm in Subjects who were Previously Dissatisfied with Sumatriptan (Right Formulation, Right Dose, Right Paradigm)

Janssen Pharmaceutical, Inc.

ALN-INT-17	A Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Alniditan Given Subcutaneously in the Acute Treatment of Migraine
ALN-INT-18	Open Evaluation of the Long-Term Efficacy, Safety and Tolerability of 1.4 mg SC Alniditan in the Acute Treatment of Migraine Attacks

Jazz Pharmaceuticals

06-008	A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects with Fibromyalgia
06-010	An Extension study for 06-008

King Pharmaceuticals

K644-07-3001	A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection with Sumatriptan Succinate using the [Tradename] Auto-injector During a Single Migraine Attack
--------------	---

Map Pharmaceuticals

MAP0004-CL-P201 A Randomized, Double-Blind, Placebo Controlled, Two-Part, Phase 2 Study of Three Doses of MAP0004 (Tempo™ DHE) in Migraineurs

Matrix Initiatives, Inc.

MTX-002 Preliminary Assessment of Zicam Migraine Relief

MTX-M2 Human Clinical Investigation of a Homeopathic Drug for Migraine Headache

MTX-M3 Human Clinical Investigation of a Homeopathic Drug for Migraine Headache

Merck & Co., Inc.

078-00 An Observer-blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine

MK-0462-081 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK-0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine

011-01 A Multi-Center, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 with Placebo and Zolmitriptan for the Acute Treatment of Migraine with or without Aura

012-01 A Multi-Center, Double-Blind, Active-Controlled, Parallel Group Study to Examine The Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine with or without Aura

075-00 A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Co-Administered with Acetaminophen for the Treatment of Acute Migraine

074-00 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated with Rizatriptan Orally Disintegrating Tablet (ODT)

COX523 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg qd vs Diclofenac Sodium 50 mg tid in Patients with Osteoarthritis

046-00 A Crossover Comparison of Rizatriptan and Sumatriptan

- 049-00 A Randomized, Triple-Blind, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability and Efficacy of Rizatriptan (Benzoate Salt) 10 mg. RPD and 5 mg RPD for the Acute Treatment of Migraine
- 054-00 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Rizatriptan 5 mg PO for the Acute Treatment of Migraine in Adolescents
- 060-00/MAX478 A Randomized, Open-Label, Two-Period, Crossover Study Comparing Preference for Rizatriptan MLT 10 mg or Sumatriptan 50 mg Tablet for the Acute Treatment of Migraine
- 125-00 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Montelukast 20 mg/day PO and Rofecoxib 25 mg/day PO for the Prophylaxis of Migraine Attacks
- 59-00 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Rizatriptan 5 mg PO for the Acute Treatment of Migraine in Adolescents
- MAX-US-RC-4/00 Cognitive Efficiency Following Migraine Therapy
- MAX547/065-00 An Open-Label Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months
- MAX550/066-00 A Multi-Center, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild

Minster Pharmaceuticals

- TON/03/07-CLIN Multi-centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension

Mylan Pharmaceuticals, Inc.

- DOT-950301 A Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-Center Trial Comparing Placebo and Three Doses of Dotarizine in the Prophylaxis of Migraine Headache

Neuralieve

- NL-2006-001 A Phase III, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive, Non-repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache

Novartis Pharmaceuticals

- COL446HUS136 A randomized, multicenter, double-blind, double-dummy, parallel-group study of acetaminophen or fluvastatin compared to placebo on the transient Post-Dose Symptoms (PDS) following an i.v. infusion of a single dose of zoledronic acid 5mg, in post-menopausal women with low bone mass
- CSPA100A2301 A 54-week, open-label, multicenter study to assess the long-term Safety and tolerability of the combination of Aliskiren 300mg/ Amlodipine 10 mg in patients with essential hypertension
- LAF237A2398 A Multi-Center, Randomized, Double-Blind, Active-Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with Type 2 Diabetes
- LAF237A23104 A Multi-Center, Double-Blind, Randomized Parallel-Group Study to Demonstrate the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd as Add-On to Metformin 500 mg bid Compared to Metformin 1000 Mg bid in Patients with Type 2 Diabetes Inadequately Controlled on Metformin 500 Mg bid Monotherapy
- CMLF237A2302 A Randomized, Double-Blind, Active-Controlled, Multi-Center Study to Compare the Effect of 24 Weeks Treatment with a Fixed Combination Therapy of Vildagliptin and Metformin to the Individual Monotherapy Components in Drug Naïve Patients with Type 2 diabetes
- CSVP100A2301 A 54-Week, Open-Label, Multi-Center Study to Assess the Long-Term Safety and Tolerability of the Combination of Aliskiren 300 mg/Valsartan 320 mg in Patients with Essential Hypertension.
- CLAF237A23119 A Multi-Center, Open-Label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 weeks of Treatment with Vidagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy in a Community-Based Practice Setting
- CHTF919N2302 An Open-Label 52-Week Study to Evaluate the Safety and Efficacy of Tegaserod (6 mg bid and 12 mg od) Given Orally for the Treatment of Opioid-Induced Constipation (OIC) in Patients with Chronic Non-Cancer Pain
- CSPP100A2352 An 8-Week, Double-Blind, Randomized, Placebo-Controlled, Multi-Factorial, Parallel-Croup, Multi-Center Study to Evaluate the Efficacy and Safety of the Fixed-Cose Combinations of Aliskiren and HCTZ (150/12.5, 150/25, 300/12.5, 300/25 mg) in Patients with Essential Hypertension

- CHTF919E2313 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Evaluation of the Efficacy and Safety of Tegaserod 6 mg bid, Administered Orally for 12 Weeks, to Patients with Chronic Constipation, Aged 65 Years and Older
- CVEA489A2302 An 8-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/ Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/ Amlodipine in Patients with Moderate to Severe Hypertension
- CSPP100A2344 A 36-Week, Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled, Optional Titration Study Comparing an Aliskiren-Based Regimen to a Lisinopril-Based Regimen in Patients \geq 65 Years Old with Systolic Essential Hypertension
- CVAH631D2301 A 6-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5 mg with Forced Titration to a Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160 mg with Forced Titration to 320 mg) as Initial Therapy in Patients with Severe Hypertension
- CVAH631BUS05 A 6-Week, Multi-Center, Randomized, Parallel-Group Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combination Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-Dose Valsartan Monotherapy (80 mg) in Managing Patients with Hypertension
- SPP100A2201 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing Aliskerin 150 mg, 300 mg, and 600 mg to Placebo and Irbesartan 150 mg in Patients with Mild-to-Moderate Hypertension
- CHTF919A2306 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy and Safety of Repeated Treatment with Tegaserod 6 mg bid and Placebo in Female Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
- CCOX189A2360 A 13-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) In Patients With Primary Knee Osteoarthritis Using Celecoxib (200 mg od) as a Comparator
- CVAH631C2301 A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Valsartan (320 mg) and Hydrochlorothiazide (12.5 and 25 mg) Combined and Alone, Valsartan 160 mg and Valsartan 160 mg/ Hydrochlorothiazide 12.5 mg in Hypertensive Patients
- CHTF919D2301 A 6-Week Randomized Double Blind Placebo-Controlled Multi-Center Study to Assess the Efficacy and Safety of Tegaserod (6m g bid) and Placebo in Female Patients with Dyspepsia

- CLAF237A2303E1 A 28-Week Extension to a Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
- CLAF237A2304E1 A 28-Week Extension to a Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy
- CLAF237A2305E1 A 28-Week Extension to a Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy
- CFAM810A2403 A Randomized, Multi-Center, Double-Blinded, Controlled Study to Compare the Effectiveness of Single Dose (1500 mg) of Famciclovir, One Day (750 mg Q12) of Famciclovir and Placebo in Patient-Initiated Episodic of Recurrent Herpes Labialis
- CFAM810AUS07 A 6-Month Open-Label, Randomized, Multi-Center Study to Evaluate the Comparative Efficacy and Safety of Oral Famvir in the Episodic (125 mg bid for 5 Days) and Suppressive Treatment (250 mg bid) of Recurrent Genital Herpes
- CSPP100A2307 An 8-Week, Randomized, Double-Blind, Parallel-Group, Multi-Center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination with Ramipril in Patients with Hypertension and Diabetes Mellitus
- CLAF237A2305 A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy
- CCOX189A2360E1 A 39-Week, Open-Label Extension to CCOX189A2360 a 13-Week Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of Lumacoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator
- CLAF237A2303 A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

- CLAF237A2304 A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled Thiazolidinedione Monotherapy
- CENA13BUS725 A Prospective, Randomized, Parallel-Cohort, Multicenter, 13-Week, Open-Label Comparative Study of the Effects of Exelon® (Rivastigmine Tartrate) 6 to 12 mg/day, Aricept® (Donepezil HCl) 5 to 10 mg/day and Reminyl® (Galantamine Bromide) 16 to 24 mg/day on CSF Cholinesterase Activity in Patients with Mild to Moderate Alzheimer's Disease

Ortho-McNeil

- CAPSS-368 Long-Term, Open-Label Safety of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents
- CAPSS-334 Efficacy of AXERT® (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy with TOPAMAX® (Topiramate)
- CAPSS-381 Topiramate Intervention to Prevent Transformation of EPIsoDic Migraine: The Topiramate INTREPID Study
- CAPSS-223 A Comparison of the Efficacy and Safety of Ultracet® (Tramadol HCL/ Acetamenophen) vs Placebo for the Acute Treatment of Migraine and Headache Pain
- CAPSS-276 A Comparison of the Efficacy and Safety of Topiramate vs Placebo for the Prophylaxis of Chronic Migraine
- CAPSS-277 A Comparison of Topiramate vs Amitriptyline in Migraine Prophylaxis
- CAPSS-316 AXERT Early Migraine Intervention Study (AEGIS): Efficacy and Safety of AXERT (Almotriptan Malate) vs Placebo for the Acute Treatment of Migraine Headache

Pfizer Pharmaceuticals

- A3191173 A Double-Blind, Parallel-Group, Randomized, Study of the Efficacy and Safety of "Continuous" use of Celecoxib vs the "Usual Use" of Celecoxib in the Treatment of Subjects with Chronic Osteoarthritis of the Hip or Knee Who Require an Anti-Inflammatory Medication for Control of Their Pain
- A4291023 A Phase 2B, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating the Efficacy and Safety of PD-0299685 for the Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

- A6061026 [S,S]- Reboxetine Dose-Range Finding Trial: A 16-week, Randomized, Double-Blind, Placebo and Pregabalin Controlled, Multi-Center Trial of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (Phn)
- A6061029 An Open-Label Extension Trial Assessing the Safety and Tolerability of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (Phn)
- A5091031 A Phase 3, Open-Label, Multi-Site, Randomized, Parallel-Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/ Atorvastatin Administered Once Daily qd Compared to Simvastatin for 6 Weeks in Subjects with Hypercholesterolemia
- A1601092 An Open-Label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers who are Dissatisfied with Rizatriptan Therapy
- 160-102 A Study of Efficacy and Safety of Oral Eletriptan in Subjects with Acute Migraine
- 160-105 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Oral Eletriptan in Adolescent Subjects Aged 12 to 17 Years with Acute Migraine
- 160-108 A Multi-Center, Randomized, Open-Label, Comparative Study of the Safety, Toleration, and Efficacy of Oral Eletriptan for Long Term Treatment of Subjects with Acute Migraine
- A1601027 Switching from Fiorinal/Fioricet to Oral Eletriptan 40 mg; Impact on Work Productivity, Quality of Life, Healthcare Use, and Subject Satisfaction in the Treatment of Acute Migraine
- P0002449 A Multi-Center Study Examining the Prevalence by Severity, Frequency, and Disability of Migraine in Adult Patients in Primary Care Practices
- A1601034 An Open-Label Study of Eletriptan 40 mg for the Acute Treatment of Migraine in Migraine Sufferers who are Dissatisfied with Excedrin Migraine[®] Treatment
- A1601048 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Comparative Study of the Efficacy and Safety of Oral Eletriptan 40 mg and Sumatriptan 100 mg Given for the Acute Treatment of Migraine
- A1601106 An Observational, Multiple-Attack Study in Migraineurs to Determine the Incidence and Impact of Migraine Relapse and Recurrence Associated with 5HT_{1B/1D} Agonist (Triptan) Treatment
- A0081059 A 6-Month, Double-Blind, Placebo-Controlled, Durability of Effect Study of Pregabalin for Pain Associated with Fibromyalgia

Pharmacia & Upjohn

638-CNS-0059-013 Axert Clinical Experience Study (ACES)

- M/3275/0011 A Long-Term Open-Label Safety Study of Almotriptan 12.5 mg Orally in Migraine Patients
- M/3275/0008 Oral Almotriptan vs. Oral Sumatriptan in a Double-Blind, Randomized, Parallel-Group Study of Cost-Effectiveness and Quality of Life in Migraine

Pozen

- LNP-201 A Randomized, Double-Blind, Single-Dose, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine
- MT100-307 A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of MT100 in the Treatment of Migraine Prodrome
- MT300-302 A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of MT300 in the Acute Treatment of Migraine
- MT 300 A Single Dose, Placebo-Controlled, Multi-Center, Dose Ranging Trial of MT 300 in Patients with Acute Migraine Headaches
- MT100-301 A Single Dose, Double-Blind, Safety and Efficacy Study of MT100, Metoclopramide Hydrochloride and Naproxen Sodium in Subjects with Acute Migraine Attacks
- MT100-302 An Open-Label, Repeat Dose, Long-Term Safety Study of MT100 in Subjects with Acute Migraine Attacks
- MT100-201 A Single Dose, Double-Blind, Dose-Ranging, Placebo-Controlled Safety and Efficacy Study of Various Doses of Naproxen Sodium and Metoclopramide in Subjects with Acute Migraine Headaches
- MT400-302 A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima TM in the Acute Treatment of Migraine Headaches
- MT400-303 An Open-Label, Repeat-Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months

Procter & Gamble

- 1995017 A Study Comparing the Analgesic Effects of the Combination of Ibuprofen Plus Caffeine Relative to Ibuprofen Alone in Subjects with Acute Tension-Type Headache

Purdue Frederick Research Company

CC90-1107 A Comparative Study Evaluating the Safety and Analgesic Efficacy of Controlled-Release Codeine with PRN Supplements of Acetaminophen and Acetaminophen with Codeine Given as Needed in Patients with Stable Low Back Pain

A Study of the Effect of Choline Magnesium Trisalicylate on Blood Pressure Control in Hypertension Patients on a Stable Medicine Regimen

QualityMetric

SBIR1R43NS-047763-01 Computerized Adaptive Assessment of Headache Impact

Sandoz Pharmaceutical Corporation

DynaCirc Assessment Trial Analysis, Regional Migraine Field Trial of DHE 45 Injection

A Study to Determine the Effectiveness and Safety of Migramist for the Acute Treatment of Migraine Headache

Schwarz Biosciences

SP906 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety Of 100 mg/Day and 300 mg/Day Lacosamide for Migraine Prophylaxis

Torrey Pines Pharmaceuticals

NGX424MIG2001A Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine

Vanguard Medica Ltd

VML/251/08 A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of a Single Dose of VML/251 (2.5 mg) in the Acute Treatment of Migraine

VML251/96/08 A 12-Month Study of VML251 in the Acute Treatment of Migraine

VML/251/06 A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of a Single Dose of VML251 (2.5 mg) in the Acute Treatment of Migraine

VML251/03 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Cardiovascular Safety of VML 251 in Patients with Known and at High Risk of Coronary Artery Disease Treating an Acute Attack of Migraine

Vernalis

VML251/00/02A Double-Blind, Placebo-Controlled, Three-Way, Cross-Over Clinical Study to Assess the Safety and Efficacy of Two Dose Regimens of Frovatriptan Compared with Placebo in Preventing Menstrually-Associated Migraine (MAM) Headaches

VML251/00/01 A Double-Blind, Placebo-Controlled, Two-Attack, Cross-Over Study to Assess the Efficacy of Frovatriptan 2.5 mg Taken for Mild Headache

VML 251-3MRM02 A Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension Phase to Assess the Efficacy, Tolerability And Safety of Oral Frovatriptan in the Prevention of Menstrually-Related Migraine (MRM) Headaches in a "Difficult to Treat" Population

Winston Laboratories

W-1001-02-01 A Double-Blind, Vehicle-Controlled, Evaluation of Intranasal Civamide in the Treatment of Episodic Cluster Headaches

WL-1002-01-02 A Phase II, Double-Blind, Multi-Center, Vehicle-Controlled Feasibility Study of the Safety and Efficacy of Intranasal Doxepin in the Prophylactic Treatment of Chronic Daily Headache

Zeneca

136-43 A Multi-Center, Long-Term Study to Maximize Migraine Relief with 311C90 (MAXIMM)

311CIL/0081 An Open, Randomized, Parallel-Group, Multi-Center Trial to Compare the Efficacy of a Stratified Treatment Regimen for Acute Migraine Attacks, in which Patients Receive Therapy According to the Grade of Their Migraine Disability at Baseline

ZD6416IL/0023 A Randomized, Double-Blind, Placebo-Controlled, Crossover, Multi-Center Trial to Determine the Analgesic Efficacy, Safety, and Tolerability of Treatment with Multiple Doses of ZD6416 1600 mg Administered Twice Daily in Adult Subjects with Post Herpetic Neuralgia

311CIL/0001 A Continuation Protocol for Subjects Who Have Participated in Previous Zolmitriptan Clinical Trials

Zogenix

ZX001-0701 A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject System in Adult Patients During Acute Migraine Attack

Clinvest, Inc. Investigator Initiated Studies

Allergan

A Double-Blind, Randomized Study Using Botox[®] (Botulinum Toxin Type A) Injections for Prevention of Disabling Headaches

Efficacy and Satisfaction with Use of Botox[®] (Botulinum Toxin Type A) as Migraine Preventive Treatment in Patients who Have Failed with a Prophylactic Medication Due to Compliance Issues

A Single-Center, Double-Blind Comparison of Botox[®] (Botulinum Toxin Type A) and Topiramate for the Prophylactic Treatment of Chronic Migraine Headaches

Astra Zeneca

Crossover Design to Measure Cognitive Efficiency of Migraineurs Before and After Treatment with Zomig-ZMT (Zolmitriptan) and Fioricet (Butabital, Acetaminophen and Caffeine)

Elan

An Open-Label Study Comparing the Tolerability and Effectiveness of Skelaxin[®] vs Flexeril When Taken with Ibuprofen in Patients with Acute Low Back Pain

GlaxoSmithKline

Evaluation of the Efficacy of Naratriptan for the Prevention and Treatment of Post Traumatic Headache Associated with Cognitive Dysfunction

Oral Sumatriptan 50 mg to Treat Self-Described Sinus Headache in Patients with Migraine Diagnosis

Oral Sumatriptan 50m g to Treat Self-Described Sinus Headache

Pathophysiology and Treatment with Sumatriptan of Migraine with "Sinus" Symptoms

Treatment of Migraine Prodrome with Naratriptan: A Pre-emptive Approach to Migraine Care

A Pre-emptive Prophylactic Research Study Utilizing Naratriptan 2.5 mg Taken When Subject Believes a Migraine is Likely to Occur and Before the Onset of Headache Symptoms

Identification of Headache among Sufferers of Previously Undiagnosed
Menstrually Associated Migraine and Treatment with Sumatriptan 100 mg

Merck

Cognitive and Economic Impact of Migraine Treatment in the Work-place with
Rizatriptan vs Placebo: Effects of Early vs Delayed Intervention

Ortho-McNeil

Evaluation of CGRP and VIP as Biological Markers for Activation of Trigeminal
and Parasympathetic Nerve Fibers in Response to "Sinus" Symptoms

Evaluation of Histamine, CGRP and VIP as Biological Markers for Activation of
Trigeminal and Parasympathetic Nerve Fibers in Response to "Sinus"
Symptoms

Regulation of CGRP Secretion in Cultured Trigeminal Neurons by Topamax

**Primary Care
Network Foundation**

The Cognitive Impact of Migraine in Children and Response to Treatment

Evaluation of Disease Burden in Subjects with Migraine

Evaluation of CGRP and VIP as Biological Markers for Activation of Trigeminal
and Parasympathetic Nerve Fibers in Response to "Sinus" Symptoms